VolitionRx Announces Acceptance of Compliance Plan by NYSE American
Rhea-AI Summary
VolitionRx (NYSE AMERICAN: VNRX) announced that on April 22, 2026 the NYSE American accepted its plan of compliance to regain listing standards. The company has until August 6, 2027 to restore required stockholders' equity thresholds and will undergo periodic reviews during the Plan Period.
The Acceptance Letter does not affect current listing or the company's SEC reporting obligations.
Positive
- NYSE American accepted Volition's compliance plan on April 22, 2026
- Company granted extension to August 6, 2027 to regain compliance
- Common stock remains listed and tradable during the Plan Period
- Plan submitted before the March 8, 2026 NYSE deadline
Negative
- Company previously found noncompliant with Sections 1003(a)(i)-(iii) on February 6, 2026
- Required stockholders' equity thresholds: $2.0M, $4.0M, $6.0M
- NYSE American may initiate delisting if compliance not regained by August 6, 2027
News Market Reaction – VNRX
In the Apr 23 session, VNRX declined 8.69%, reflecting a notable negative market reaction. Argus tracked a peak move of +17.8% during that session. Argus tracked a trough of -6.2% from its starting point during tracking. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 20 | Product launch | Positive | -8.7% | Launch of rNuQ™ webshop expanding Nu.Q® Discover commercialisation. |
| Mar 31 | Earnings update | Positive | -1.0% | 2025 revenue growth, lower operating expenses, reduced net loss and cash burn. |
| Mar 31 | Non-dilutive funding | Positive | +6.3% | €2.0M non-dilutive Belgian funding to support Nu.Q® portfolio initiatives. |
| Mar 30 | Clinical study data | Positive | -3.4% | Mayo Clinic study showing elevated Nu.Q® markers in trauma patients with VTE risk. |
| Mar 26 | Conference abstract | Positive | +0.9% | ELCC abstract on Nu.Q®-based risk stratification in non-small cell lung cancer. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent VNRX news has often seen negative or muted reactions even to seemingly positive operational and funding developments, with more divergences than alignments.
Over the past month, VNRX has reported multiple operational and financing milestones, including 86% 2025 revenue growth backing an rNuQ™ webshop launch, full-year 2025 results with revenue up 40% and expenses reduced, and over €2.0 million in non-dilutive Belgian funding. Scientific updates from Mayo Clinic trauma studies and lung cancer risk stratification abstract presentations highlighted Nu.Q® platform potential. Despite this, 24-hour price reactions have often been negative or modest, underscoring cautious sentiment ahead of today’s listing compliance update.
Key Terms
nyse american regulatory
company guide regulatory
continued listing standards regulatory
plan of compliance regulatory
delisting proceedings regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
As previously reported, on February 6, 2026, the Company received a notice from the NYSE American stating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(i) of the NYSE American Company Guide (the "Company Guide") requiring a company to have stockholders' equity of at least
The Company was required to submit a plan to the NYSE American by March 8, 2026, advising of actions it has taken or will take to regain compliance with the continued listing standards by August 6, 2027. The Company submitted a plan prior to the deadline.
On April 22, 2026, the Company received a notification (the "Acceptance Letter") from the NYSE American that the Company's previously submitted plan to regain compliance with the NYSE American's listing standards (the "Plan") was accepted. In the Acceptance Letter, the NYSE American granted the Company until August 6, 2027 (the "Plan Period") to regain compliance with the continued listing standards.
During the Plan Period, the Company will be subject to periodic review by the NYSE American on its progress with the goals and initiatives outlined in the Plan. The Company intends to take all reasonable measures available to regain compliance with Sections 1003(a)(i), (ii) and (iii) of the Company Guide during the Plan Period. If the Company does not regain compliance with the NYSE American listing standards by August 6, 2027, or if the Company does not make sufficient progress consistent with the Plan during the Plan Period, then NYSE American may initiate delisting proceedings.
The Acceptance Letter has no immediate impact on the listing of the Company's shares of common stock, which will continue to be listed and traded on the NYSE American during the Plan Period, subject to the Company's compliance with the other listing requirements of the NYSE American. The Acceptance Letter does not affect the Company's ongoing business operations or its reporting requirements with the Securities and Exchange Commission.
About Volition
Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.
Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.
Volition's research and development activities are centered in
Media Enquiries
Louise Batchelor, Volition mediarelations@volition.com
+44 (0)7557 774620
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements reflect the current beliefs and expectations of management and include statements regarding the Company's expectations surrounding regaining compliance with the NYSE American's continued listing standards, and actions of the Company and/or the NYSE American to be taken with respect to matters discussed in the notice and the Acceptance Letter. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Although Volition believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to be correct.
Forward-looking statements are subject to risks and uncertainties that may cause Volition's actual activities or results to differ materially from those indicated or implied by any forward-looking statement, including, without limitation, due to risks and uncertainties related to the Company's ability to regain compliance with the listing standards set forth in the Company Guide by August 6, 2027, as well as the risks disclosed in other documents Volition files from time to time with the SEC, including Volition's Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict.
Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.
View original content:https://www.prnewswire.com/news-releases/volitionrx-announces-acceptance-of-compliance-plan-by-nyse-american-302751633.html
SOURCE VolitionRx Limited